Journal of Cancer Clinical Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us 44-1258650017

Short Communication - Journal of Cancer Clinical Research (2020) Volume 3, Issue 3

Obesity correlation with metastases development and response to first-line metastatic chemotherapy in breast cancer

To compare breast cancer metastases between obese and non-obese women and to evaluate the effect of first-line metastatic chemotherapy in each group A retrospective study was performed in an educational institute in Ireland. The study consisted of two parts: the first part was a comparative analysis of metastases development in obese (arm A) and non-obese patients (arm B). The second part was a comparison between both arms in relation to their response to first-line metastatic chemotherapy and their survival data. Between 2009 and 2014, we reviewed 118 patients with metastatic breast cancer. All the patients fulfilled our inclusion criteria. In all, 48% of patients were obese and 52% were non obese. There were no statistically significant differences between the two groups. For arms A and B, the median interval between initial cancer diagnosis and distant metastases development (distant metastases-free survival) was 5.8 versus 7.6 years, respectively (P value 0.04). Earlier visceral (liver and lung) metastases were observed in obese compared to non-obese women (P values were 0.05 and 0.04, respectively). The most commonly used chemotherapy was weekly paclitaxel. Our treatments showed significantly better treatment response and better survival results in non-obese women than in obese ones, who were premenopausal with performance state 2, pathological grade 3, and four or more positive lymph nodes.

Author(s): Mohammed Osman

Abstract Full Text PDF